In a special comment, Dr Brendan Shaw, the principal of Shawview Consulting, former CEO of MS and and assistant director-general of the IFPMA, says the PBS and Australian pharmaceutical policy have suffered some shocks in the past but nothing compares to COVID-19.

Latest Video
New Stories
-
Radiopharm Theranostics reports Preclinical Lu177-B7H3-mAb data
June 2, 2025 - - Australian Biotech -
Neurotech announces positive human PK study results for NTI164
June 2, 2025 - - Australian Biotech -
Cardiex receives TGA approval for CONNEQT Pulse arterial health monitor
June 2, 2025 - - Australian Biotech -
Pharmac minister sworn in as New Zealand's Deputy Prime Minister
June 1, 2025 - - Latest News -
An opportunity for reflection on the need to humanise PBS decision-making
June 1, 2025 - - Latest News -
Ipsen's Julien Dagher promoted to European leadership role
June 1, 2025 - - Latest News -
Daiichi Sankyo secures certification as Great Place to Work
June 1, 2025 - - Latest News